A Single Arm, Open-Label Phase I Study to Evaluate the Safety and Tolerability of ISC-hpNSC Injected Into the Striatum and Substantia Nigra of Patients With Parkinson's Disease

Trial Profile

A Single Arm, Open-Label Phase I Study to Evaluate the Safety and Tolerability of ISC-hpNSC Injected Into the Striatum and Substantia Nigra of Patients With Parkinson's Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs ISC-hpNSC (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; First in man
  • Sponsors Cyto Therapeutics
  • Most Recent Events

    • 07 Sep 2017 According to an International Stem Cell Corporation media release, two more patients with Parkinson's disease were successfully transplanted with ISC-hpNSC cells at the Royal Melbourne Hospital (RMH), in July and August, 2017. These two patients are part of the second cohort clinical trial being treated for Parkinson's disease.
    • 14 Aug 2017 According to an International Stem Cell Corporation media release, the fifth patient (the first patient of the second cohort) has been successfully transplanted with ISC-hpNSC cells.
    • 09 May 2017 According to an International Stem Cell Corporation media release, the company received approval to start second cohort (patients receiving higher dose of 50,000,000 of ISC-hpNSC) from Data Safety Monitoring Board after reviewing safety data from the first cohort.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top